Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|July 13, 2017
eClinicalHealth Introduces Clinpal EDC Patient-Centric Cloud Platform
Advertisement
Stirling, UK, 13 July 2017-eClinicalHealth introduced Clinpal EDC, an application for data capture on a single cloud platform that enables an intuitive experience for patients and sites as well as all sponsor and CRO stakeholders.
With over five years of development and use in numerous live trials, Clinpal EDC is created for Phase II through Phase IV post-marketing studies, observational studies, and registries, with no upper limit on the number of sites or patients.
“Clinpal EDC offers a modern and advanced cloud approach to electronic data capture that provides natural workflows to sites, sponsors, and CROs, while involving patients in the trial lifecycle,” said Doug Bain, Chief Technology Officer at eClinicalHealth.
Clinpal EDC is a single cloud platform to recruit patients through targeted websites and social networks, qualify and enroll them, and then collect data for retention and protocol compliance throughout the clinical trial process.
“Our EDC platform is unique in that it has shortened delivery times, reduced costs, and enabled sponsors to collect source data directly from thousands of patients while meeting global regulatory requirements,” said Ian Mills, Lead Architect of Clinpal EDC.
The Clinpal EDC package has a patient-centric focus to EDC, is built on a cloud platform, and is suited for commercial, academic, and hospital-based research teams.
To find out more about Clinpal EDC, click
About eClinicalHealth
For over 5 years, Clinpal EDC has been capturing data from patients in studies across 41 countries on 6 continents in virtually all local languages. These projects have integrated a variety of biometric data and range from small proof-of-concept trials to large global patient registries.
Contact: Suzie Harvey
Email:
Office:
Web:
Join our community:
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5